Cargando…

Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study

BACKGROUND: Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed to characterize the relative frequency and burden of pre- and post-headache symptoms in people with migraine using data collected through the Chronic Migraine Epidemiology and Outcomes –...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipton, Richard B., Lanteri-Minet, Michel, Leroux, Elizabeth, Manack Adams, Aubrey, Contreras-De Lama, Janette, Reed, Michael L., Fanning, Kristina M., Buse, Dawn C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634176/ https://www.ncbi.nlm.nih.gov/pubmed/37940856 http://dx.doi.org/10.1186/s10194-023-01683-1

Ejemplares similares

Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Medication Overuse and Headache Burden: Results From the CaMEO Study
por: Schwedt, Todd J., et al.
Publicado: (2021)

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability
por: Lipton, Richard B., et al.
Publicado: (2016)

The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2020)

The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results
por: Adams, Aubrey Manack, et al.
Publicado: (2015)

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2019)

Characterizing opioid use in a US population with migraine: Results from the CaMEO study
por: Lipton, Richard B., et al.
Publicado: (2020)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2023)

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale
por: Lipton, Richard B., et al.
Publicado: (2017)

EHMTI-0169. Trajectories of headache days over one year (5 waves) in chronic and episodic migraineurs participating in the chronic migraine epidemiology and outcomes (cameo) study
por: Lipton, RB, et al.
Publicado: (2014)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

EHMTI-0099. Migraineur perception regarding family burden from chronic migraine: results of the CAMEO (chronic migraine epidemiology & outcomes) study
por: Buse, DC, et al.
Publicado: (2014)

Consistency vs. switching triptan treatment and headache-related disability: Results of the American migraine prevalence & prevention study
por: Buse, DC, et al.
Publicado: (2013)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

Comorbid pain and migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study
por: Scher, Ann I., et al.
Publicado: (2017)

Depression and risk of transformation of episodic to chronic migraine
por: Ashina, Sait, et al.
Publicado: (2012)

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design
por: Serrano, Daniel, et al.
Publicado: (2017)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
por: Manack Adams, Aubrey, et al.
Publicado: (2023)

Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Rothrock, John F., et al.
Publicado: (2019)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Major life events, stress appraisal, and migraine: results of the American Migraine Prevalence and Prevention (AMPP) study
por: Manack, AN, et al.
Publicado: (2013)

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
por: Young, William B., et al.
Publicado: (2019)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

Adding acute treatments for patients on triptans: Results of the American Migraine Prevalence & Prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

COVID-19 and SARS-CoV-2 Vaccines: A Cameo Role for Headache
por: Martelletti, Paolo
Publicado: (2023)

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
por: Schwedt, Todd J., et al.
Publicado: (2018)

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
por: Blumenfeld, Andrew M, et al.
Publicado: (2019)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2023)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
por: Diener, Hans Christoph, et al.
Publicado: (2021)

Risk of medication overuse headache across classes of treatments for acute migraine
por: Thorlund, Kristian, et al.
Publicado: (2016)

Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches
por: Mannix, Sally, et al.
Publicado: (2016)

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

SysML in action with Cameo Systems Modeler
por: Casse, Olivier
Publicado: (2017)

SysML in action with Cameo Systems Modeler /
por: Casse, Olivier
Publicado: (2017)

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qks0jebn1lr5kkms9nv00kpjr7